Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus

September 30, 2021 Auto Bot Clinical Trials, Janssen, P-III, respiratory syncytial virus 0

Shots:

  • The company initiates a P-III EVERGREEN study to evaluate the efficacy, safety & immunogenicity of RSV vaccine vs PBO in 23000 adults aged ≥60yrs. with LRTD caused by RSV across North America, EU, Africa, America & Asia
  • The positive P-IIb CYPRESS data further supports the initiation of the P-III EVERGREEN study & the results from the P-IIb CYPRESS study will be presented at IDWeek 2021
  • In Sep’19, the RSV vaccine has received the BTD from the US FDA to prevent LRTD caused by RSV in adults aged ≥60yrs. In Nov’20, the EMA’s CHMP has recommended the vaccine for the PRIME designation based on the clinical data

Click here to­ read full press release/ article | Ref: J&J | Image: Reuters

The post Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus first appeared on PharmaShots.